Analysts See $-0.05 EPS for Profound Medical Corp. (PRN); 3 Analysts Bullish Danone (DANOY)

February 12, 2018 - By Michael Collier

Analysts expect Profound Medical Corp. (CVE:PRN) to report $-0.05 EPS on March, 5.They anticipate $0.05 EPS change or 50.00% from last quarter’s $-0.1 EPS. After having $-0.09 EPS previously, Profound Medical Corp.’s analysts see -44.44% EPS growth. The stock decreased 5.17% or $0.06 during the last trading session, reaching $1.1. About 87,345 shares traded. Profound Medical Corp. (CVE:PRN) has 0.00% since February 12, 2017 and is . It has underperformed by 16.70% the S&P500.

Among 5 analysts covering Danone SA (OTCMKTS:DANOY), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Danone SA had 5 analyst reports since September 2, 2015 according to SRatingsIntel. On Wednesday, January 6 the stock rating was initiated by HSBC with “Buy”. Zacks upgraded Danone (OTCMKTS:DANOY) on Wednesday, September 2 to “Hold” rating. As per Monday, October 3, the company rating was initiated by Bernstein. The rating was downgraded by Davy Research on Thursday, February 9 to “Neutral”. The rating was upgraded by Societe Generale on Thursday, November 19 to “Buy”. See Danone (OTCMKTS:DANOY) latest ratings:

The stock decreased 0.79% or $0.125 during the last trading session, reaching $15.695. About shares traded. Danone (OTCMKTS:DANOY) has 0.00% since February 12, 2017 and is . It has underperformed by 16.70% the S&P500.

Danone operates as a food company worldwide. The company has market cap of $48.37 billion. The Company’s Fresh Dairy Products division produces and markets yogurts, fermented fresh dairy products, and specialized dairy products under the Oikos, Danio, Activia, Danonino, Fruchtswerge, Danoninho, Danimals, Serenito, Tëma, Actimel, Danacol, Densia, Danette, Fantasia, Danissimo, YoCrunch, Vitalinea, Light & Fit, Taillefine, and Ser brands. It has a 21.62 P/E ratio. The companyÂ’s Waters division offers packaged natural, flavored, and vitamin-enriched water under the evian, Volvic, Badoit, Aqua, Mizone, Bonafont, Villavicencio, Villa del Sur, Fontvella, Lanjarón, and Zywiec Zdroj brands.

Profound Medical Corp., a medical device company, engages in developing and commercializing novel technologies to ablate the prostate gland in prostate cancer patients in Canada. The company has market cap of $80.43 million. It offers TULSA-PRO, a system for precise ablation of the prostate. It currently has negative earnings.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>